Strong Intellectual Property Portfolio

MetrioPharm AG Patent Protection

News

MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients - 2022-Dec-08

MP1032 has many advantages over other available antivirals: it can be conveniently administered orally and has both anti-inflammatory and anti-Sars-CoV-2 properties, making it an ideal candidate to prevent a so-called cytokine storm.

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» iMPact Homepage

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact

Social

  

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Phone: +41 44 552 7190

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

Imprint
Privacy policy (We don’t collect cookies)
Sitemap